Synopsis Continuous intravenous epoprostenol was the first treatment approved for pulmonary arterial hypertension (PAH) but administration through a central venous line carries risks of thrombosis and sepsis, in children. Thus, the aim of the present study was to evaluate the safety, efficacy and management of subcutaneous (SC) treprostinil in children with PAH. This week’s “MED FACT” discusses a clinical trial from International Journal of Cardiology, “Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension”.
Authors: Marilyne Levy et.al. Key Takeaways: Subcutaneous treprostinil infusion is an effective therapy without serious side effects in children with PAH. Objective: To evaluate the safety, efficacy and management of subcutaneous (SC) treprostinil in children with PAH Study Type: Randomized trial…
